期刊文献+

左乙拉西坦添加治疗儿童难治性癫痫部分性发作的临床研究 被引量:21

下载PDF
导出
摘要 癫痫(epilepsy)是一种慢性的、反复出现的发作性疾病,儿童癫痫中,20%~30%的患儿发作不能得到有效控制,成为难治性癫痫(intractableepilepsy,IE)或称耐药性癫痫。左乙拉西坦(LEV)自2007年在我国上市以来,国内关于儿童添加LEV治疗难治性癫痫部分性发作的报道较少。本文就我院72例难治性癫痫部分性发作的患儿进行添加LEV治疗,随访观察其疗效和安全性。为进一步合理使用该药积累经验,现报告如下。
出处 《中国药物与临床》 CAS 2012年第9期1194-1196,共3页 Chinese Remedies & Clinics
  • 相关文献

参考文献10

  • 1Labate A, Colosimo E, Gambardella A,et al. Levetiracetam in patients with generalized epilepsy andmyoclonic seizures: an open label study. Seizure,2006,15(3) :214-218.
  • 2Kaminski RM, Matagne A, Patsalos PN, et al. Benefit of combina- tion therapy in epilepsy:a review of the preclinical evidence with levetiracetam. Epilepsia, 2009,50(3) : 387-397.
  • 3Steinhof B J, Trink E, Wieser HG. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Ger- many and Switzerland. Seizure,2005,14(7):490-496.
  • 4Rafal MK,Michel G,Karine L,et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant ef-ficacy of levetiracetam. Epilepsia,2009,50(7) : 1729-1740.
  • 5Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther, 2000,85 : 77-85.
  • 6吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 7Grosso S, Cordelli D, Franzoni E, et al. Efficacy and safety of lev- etiracetam in infants and young children with refractory epilepsy. Seizure, 2007,16(4) : 345-350.
  • 8翟琼香,桂娟,张宇昕.左乙拉西坦治疗儿童癫51例自身对照研究[J].实用儿科临床杂志,2008,23(9):698-699. 被引量:21
  • 9Opp J,Tuxhorn I,May T,et al. Levetiracetam in children with re- fractory epilepsy:a multicenter open label study in Germany. Seizure, 2005,14(7) :476-484.
  • 10Wu T,Chen CC,Chen TC,et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study. Epilepsy Behav, 2009,16 (3) : 468- 474.

二级参考文献23

  • 1周宏,孙妍萍.妥泰治疗小儿癫痫疗效观察[J].滨州医学院学报,2006,29(4):294-295. 被引量:5
  • 2Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg·day^-1 in adult patients with refractory epilepsy. Seizure,2003, 12: 141-149.
  • 3Beran RG, Berkovic SF, Black AB, et al. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partialonset seizures: a muhicenter, open-label single-arm study.Epilepsy Res, 2005, 63: 1-9.
  • 4Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther, 2000, 85: 77-85.
  • 5Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia, 2001, 42 Suppl 4: 13-18.
  • 6Rigo JM, Nguyen L, Belachew S, et al. Levetiracetam: novel modulation of ionotropic inhibitory receptors. Epilepsia, 2000, 41Suppl 7 :S35.
  • 7Zona C, Niespodziany I, Marchetti C, et al. Levetiracetam does not modulate neuronal voltage-gated Na^+ and T-type Ca^2+ currents. Seizure, 2001, 10: 279-286.
  • 8Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb 1.059 ) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol, 1995, 286:137-146.
  • 9Niespodziany I, Kltigaard H, Margineanu DG. Levetiracetam:modulation of high voltage-activated Ca^2+ current in CA1 pyramidal neurons of rat hippocampal slices. Epilepsia, 2000, 41 Suppl 7 : 37.
  • 10Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of act on? Neuropharmacology, 2003, 45 : 661-667.

共引文献61

同被引文献319

引证文献21

二级引证文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部